Citations

Clear

1432 citation(s) found for "Uk, Nathan".

P14.86 Bevacizumab-associated intracerebral hemorrhage in patients with CNS malignancy: A single-center retrospective cohort study
Clarke, Nathan, Ruff, Michael W. , Clarke, N

Mayo Clinic

Neuro-Oncology | September 6, 2019 | Volume: 21 | Issue: Supplement_3 | Pages: iii88-iii88

10.1093/neuonc/noz126.321 Get It

Abstract BACKGROUND Gliomas are a known risk factor for the development of spontaneous intracranial hemorrhage (ICH) independent of therapies directed against them, with studies reporting an incidence of 1.9–3.8%. Bevacizumab (BEV) is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF) FDA approved for recurrent glioblastoma. ICH is commonly considered to be a potential adverse effect of BEV use in patients with glioma, with previous retrospective studies describing incidence of intracerebral hemorrhage ranging from 1.9–3.3%. Material and METHODS We performed a single center (Mayo Clinic, Rochester, MN) retrospective chart review of all patients who received BEV therapy at our institution for a diagnosis of primary CNS malignancy. We used ICD-9 and ICD-10 codes to identify adult patients with primary CNS neoplasms that subsequently developed ICH. RESULTS We screened 10,507 adult patients with a diagnosis of primary CNS neoplasm treated at our center from 01/31/2008 to 12/31/2018 and found 644 patients treated with bevacizumab. Of these, 23 (3.6%) suffered an ICH within 12 weeks of a BEV infusion (median 9 days post infusion, 1–24 IQR). The dose of BEV in all hemorrhages was either 10 mg/kg every two weeks (n = 21) or 15 mg/kg every three weeks (n = 2). No patients treated with infusions at 7.5 mg/kg every three weeks (n = 79) or 5 mg/kg every two weeks (n = 17) suffered ICH events, however this did not meet significance (P = 0.06) when compared to patients on 10 mg/kg or above. The median ICH score was 1 (0–2 IQR). There was an increase in ECOG scores documented at clinical follow up following the hemorrhage compared to the pre-hemorrhage functional status (ECOG 3.28 versus 1.2, p = < 0.0001), with 13 patients (56%) having developed severe debility or death (ECOG 4 n = 3, ECOG 5 n = 10). CONCLUSION In our single-center cohort of patients with a primary diagnosis of CNS neoplasms treated with BEV, ICH occurred in 3.6% of patients. Those who experienced an ICH in proximity to BEV infusion had significant morbidity and mortality with a clear decline in functional status. There was a signal of dose response as far as ICH incidence in our cohort with dosages 10 mg/kg per infusion or above.
Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms
Velamala, Pruthvi, Song, Louis M. Wong Kee , Viggiano, Thomas R., Bruining, David H. , Rajan, Elizabeth , Gostout, Christopher J., Kraichely, Robert E., Buttar, Navtej , Schroeder, Kenneth W., Larson, Mark V., Sweetser, Seth , Sedlack, Robert, Sinicrope, Stephen N. , Della’Zanna, Gary , Noaeill, Joni S., Meyers, Jeffrey P., Foster, Nathan R. , Velamala, Pruthvi R, Buttar, Navtej S, Kisiel, John B , Sweetser, Seth R, Sedlack, Robert R, Richmond, Ellen S. , Umar, Asad, Della'Zanna, Gary, Sinicrope, Stephen N , Sinicrope, Frank A. , Kisiel, John B. , Umar, Asad

Mayo Clinic

Cancer Prevention Research | September 4, 2019 | Volume: 12 | Issue: 11 | Pages: 821-830

10.1158/1940-6207.capr-19-0167 | PMID 31484660 Get It

Abstract Difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, was shown to act synergistically with a NSAID for chemoprevention of colorectal neoplasia. We determined the efficacy and safety of DFMO plus aspirin for prevention of colorectal adenomas and regression of rectal aberrant crypt foci (ACF) in patients with prior advanced adenomas or cancer. A double-blinded, placebo-controlled trial was performed in 104 subjects (age 46–83) randomized (1:1) to receive daily DFMO (500 mg orally) plus aspirin (325 mg) or matched placebos for one year. All polyps were removed at baseline. Adenoma number (primary endpoint) and rectal ACF (index cluster and total) were evaluated at a one year colonoscopy. ACF were identified by chromoendoscopy. Toxicity was monitored, including audiometry. Eighty-seven subjects were evaluable for adenomas or ACF modulation (n = 62). At one year of treatment, adenomas were detected in 16 (38.1%) subjects in the DFMO plus aspirin arm (n = 42) versus 18 (40.9%) in the placebo arm (n = 44; P = 0.790); advanced adenomas were similar (n = 3/arm). DFMO plus aspirin was associated with a statistically significant reduction in the median number of rectal ACF compared with placebo (P = 0.036). Total rectal ACF burden was also reduced in the treatment versus the placebo arm relative to baseline (74% vs. 45%, P = 0.020). No increase in adverse events, including ototoxicity, was observed in the treatment versus placebo arms. While adenoma recurrence was not significantly reduced by one year of DFMO plus aspirin, the drug combination significantly reduced rectal ACF number consistent with a chemopreventive effect.
A conditional mouse model of complex II deficiency manifesting as Leigh‐like syndrome
Khazal, Fatimah Al, Holte, Molly Nelson, White, Thomas A. , LeBrasseur, Nathan, Iii, L James Maher, Bolon, Brad , White, Thomas A., LeBrasseur, Nathan K. , III, Louis James Maher

Mayo Clinic

The FASEB Journal | August 30, 2019 | Volume: 33 | Issue: 12 | Pages: 13189-13201

10.1096/fj.201802655rr | PMID 31469588 Get It

Leigh syndrome embodies degenerative disorders with a collection of symptoms secondary to inborn errors of metabolism. Combinations of hypomorphic and loss‐of‐function alleles in many genes have been shown to result in Leigh syndrome. Interestingly, deficiency for the tricarboxylic acid cycle enzyme succinate dehydrogenase (SDH) can lead to Leigh‐like syndrome in some circumstances and to cancer (paraganglioma, renal cell carcinoma, gastrointestinal stromal tumor) in others. In our experiments originally intended to create an inducible whole‐body SDH‐loss mouse model of tumorigenesis, we generated a condition reminiscent of Leigh‐like syndrome that is lethal to mice within 4 wk. Remarkably, as has been shown for other mitochondrial diseases, chronic hypoxia offers substantial protection to mice from this condition after systemic SDH loss, allowing survival in the context of profoundly impaired oxidative metabolism.—Al Khazal, F., Holte, M. N., Bolon, B., White, T. A., LeBrasseur, N., Maher, L. J. III. A conditional mouse model of complex II deficiency manifesting as Leigh‐like syndrome. FASEB J. 33, 13189–13201 (2019). www.fasebj.org
The Search for Optimal Stereotactic Body Radiotherapy Dose in Inoperable, Centrally Located Non–Small-Cell Lung Cancer Continues
Mohindra, Pranshu , Yu, Nathan Y. , Ashman, Jonathan B. , Daniels, T.B., Merrell, Kenneth W. , Daniels, Thomas B, Schild, Steven E. , Mohindra, Pranshu , Sio, Terence T.

Mayo Clinic

Journal of Clinical Oncology | August 29, 2019 | Volume: 37 | Issue: 29 | Pages: 2697-2699

10.1200/jco.19.01330 | PMID 31465261 Get It

Senolytics in Idiopathic Pulmonary Fibrosis: Preliminary Results from a First-in-Human, Open-Label, Pilot Study
Pascual, Rodolfo M. , Hashmi, Shahrukh K. , Kirkland, James L. , Musi, Nicolas , Nambiar, Anoop M. , Justice, Jamie N. , Tchkonia, Tamar , LeBrasseur, Nathan K. , Kritchevsky, Stephen B.

Mayo Clinic

B17. ADVANCES IN ILD THERAPY | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2639-A2639

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2639 Get It

Impact of Parenchymal Lung Disease in Echocardiographic Estimate of Pulmonary Artery Pressure in Sarcoidosis Patients
Huitema, Marloes P. , Post, Marco C. , Grutters, Jan C., Shlobin, Oksana A. , Nathan, Steven D. , Wells, Athol U. , Culver, Daniel A. , Barney, Joseph B. , Porquera, Eva M. Carmona, Alhamad, Esam H. , Scholand, Mary Beth , Ganesh, Sivagini, Lower, E.E., Baughman, Robert P. , Engel, PJ, Kouranos, Vasileios , Gupta, Rohit , Wijsenbeek, Marlies

Mayo Clinic

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5081-A5081

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5081 Get It

Dasatinib and Quercetin Reverse Hyperoxia-Induced Airway Hyperreactivity in a Murine Model of Premature Airways Disease
Parikh, Pavan , Britt, Rodney D. , Roesler, A.M., Roos, B., Manlove, L., Kirkland, James L. , Wicher, Sarah A. , LeBrasseur, Nathan K. , Pabelick, Christina M. , Prakash, Y. S.

Mayo Clinic

B29. MECHANISMS FOR AIRWAY HYPERRESPONSIVENESS: FROM CELL TO ORGANISM | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A2858-A2858

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2858 Get It

Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism
Lindström, Sara , Wang, Lu , Smith, Erin N. , Gordon, William, Vlieg, Astrid van Hylckama , Andrade, Mariza de , Brody, Jennifer A. , Pattee, Jack , Haessler, Jeffrey, Brumpton, Ben , Suchon, Pierre , Chen, Ming‐Huei , Germain, Marine , Wiggins, Kerri L. , Brækkan, Sigrid K. , Armasu, Sebastian M. , Jackson, Rebecca D., Giulianini, Franco, Puurunen, Marja , Ibrahim, Manal , Heckbert, Susan R. , Natarajan, Pradeep , Klarin, Derek , Program, The Million Veteran, Vries, Paul S. de , Sabater‐Lleal, Maria , Group, The CHARGE Hemostasis Working, Bammler, Theo K. , Frazer, Kelly A. , McCauley, Bryan M. , Pankow, James S. , Reiner, Alex P. , Gabrielsen, Maiken E. , Kim, Jihye , McKnight, Barbara, Hansen, J.-B., Heit, John A. , Tang, Weihong , Morange, Pierre‐Emmanuel , Johnson, Andrew D. , Kabrhel, Christopher , Trégouët, David‐Alexandre , Smith, Nicholas L. , Assimes, Themistocles L. , Ballantyne, Christie M. , Hansen, John‐Bjarne , Frazer, Kelly A , de Andrade, Mariza , Assimes, Themistocles L , Wiggins, Kerri L , Ballantyne, Christie M , Natarajan, Pradeep , Braekkan, Sigrid K , Germain, Marine , Brumpton, Ben , Sabater-Lleal, Maria , Pankow, James S , Tang, Weihong , Brody, Jennifer A , Chasman, Daniel I. , Turman, Constance , MacDonald, James W. , Pankratz, Nathan , Nielsen, Jonas Bille , Damrauer, Scott M , Program, The Million Veteran, Huffman, Jennifer E. , Group, The CHARGE Hemostasis Working, Taylor, Kent D. , Deleuze, Jean‐François , O'Donnell, Chris J., Kraft, Peter , Rosendaal, Frits R , Psaty, Bruce M. , Kooperberg, Charles , Hveem, Kristian , Ridker, Paul M.

Mayo Clinic

Blood | August 16, 2019 | Volume: 134 | Issue: 19 | Pages: 1645-1657

10.1182/blood.2019000435 | PMID 31420334 Get It

In this work related to familial aggregation of familial venous thromboembolism, the investigators report genomic and transcriptomic association of 16 novel susceptibility loci for venous thromboembolism.
Time of Season and Game Segment Is Not Related to Likelihood of Lower-Limb Injuries: A Meta-Analysis
Doyle, Tim L. A. , Schilaty, Nathan D. , Hewett, Timothy E. , Schilaty, Nathan D , Webster, Kate E.

Mayo Clinic

Clinical Journal of Sport Medicine | August 14, 2019 | Volume: 31 | Issue: 3 | Pages: 304-312

10.1097/jsm.0000000000000752 | PMID 31415020 Get It

Objective: Fatigue due to game play is often cited as a factor in musculoskeletal injuries; however, it is unclear whether or not this view is supported by published research findings. Given the importance researchers and practitioners place on the potential effects of game play with respect to injury, it is important to understand what inferences can be drawn from the collective research in this realm. This meta-analysis will consider the time of season and segment of the game, as it relates anterior cruciate ligament (ACL), groin, and hamstring injury occurrence. Data Sources: Database searches were run in PubMed, MEDLINE, SportDiscus, CINAHL, and Ausport, in addition to the inclusion of articles identified manually. Study Selection: Search terms were chosen to identify articles related to each of the 3 injuries of interest. There were no date limitations placed on the articles, as such, all published articles listed in the databases up to November 2017 were eligible for selection if they met the search criteria. Data Extraction: Initial searches yielded 1349 articles, and this was eventually reduced to 15 articles deemed suitable for inclusion in the meta-analysis, which provided 21 data sets. Data Synthesis: Comparing the first half with the second half of the season, there were no differences in ACL, groin, or hamstring injury occurrences [ACL: odds ratio (OR), 1.27; confidence interval (CI), 0.43-3.78, groin: OR, 1.79; CI, 0.63-5.06, and hamstring: OR, 1.16; CI, 0.88-1.53]. Similarly, there were no differences in injury occurrence between the first and second halves of the game for the ACL or hamstring injuries (ACL: OR, 0.43; CI, 0.47-7.92, hamstring: OR, 0.85; CI, 0.58-1.24). Conclusions: Findings from this meta-analysis determined that time in season or time in game does not influence risk of the ACL, groin, or hamstring injury. Commonly, many studies did not provide sufficient detail to be included in the meta-analysis. Consequently, it is recommended that future studies report data related to the timing of the injury within the season or game.
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
Dubey, Divyanshu , David, William S., Amato, Anthony A. , Reynolds, Kerry L. , Clement, Nathan F., Chute, Donald F., Mooradian, Meghan J. , Sullivan, Ryan J. , Guidon, Amanda C. , Cohen, Justine V, Lawrence, Donald P. , Dubey, Divyanshu , Cohen, Justine Vanessa

Mayo Clinic

Neurology | August 13, 2019 | Volume: 93 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000008091 | PMID 31405908 Get It